Title: European Academy of Allergy and Clinical Immunology task force report on ‘dose-response relationship in allergen-specific immunotherapy’
Abstract: AllergyVolume 66, Issue 10 p. 1345-1359 ORIGINAL ARTICLE European Academy of Allergy and Clinical Immunology task force report on ‘dose–response relationship in allergen-specific immunotherapy’ M. A. Calderón, M. A. Calderón National Heart and Lung Institute, Imperial College London, London, UKSearch for more papers by this authorD. Larenas, D. Larenas Hospital Médica Sur, Mexico City, MexicoSearch for more papers by this authorJ. Kleine-Tebbe, J. Kleine-Tebbe Allergy & Asthma Center Westend, Berlin, GermanySearch for more papers by this authorL. Jacobsen, L. Jacobsen Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, DenmarkSearch for more papers by this authorG. Passalacqua, G. Passalacqua Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, Genoa, ItalySearch for more papers by this authorP. A. Eng, P. A. Eng Section of Allergy and Pulmonology, Children’s Hospital Aarau and Lucerne, SwitzerlandSearch for more papers by this authorE. M. Varga, E. M. Varga Department of Paediatrics, Respiratory and Allergic Disease Division, Medical University Graz, Graz, AustriaSearch for more papers by this authorE. Valovirta, E. Valovirta Suomen Terveystalo Allergy Clinic, Turku, FinlandSearch for more papers by this authorC. Moreno, C. Moreno Seccion de Alergia, Hospital Reina Sofía, Cordoba, SpainSearch for more papers by this authorH. J. Malling, H. J. Malling Allergy Unit, University Hospital, Copenhagen, DenmarkSearch for more papers by this authorE. Alvarez-Cuesta, E. Alvarez-Cuesta Allergy Division, Ramon & Cajal University Hospital, Alcala de Henares University, Madrid, SpainSearch for more papers by this authorS. Durham, S. Durham National Heart and Lung Institute, Imperial College London, London, UKSearch for more papers by this authorP. Demoly, P. Demoly University Hospital of Montpellier, Montpellier, FranceSearch for more papers by this author M. A. Calderón, M. A. Calderón National Heart and Lung Institute, Imperial College London, London, UKSearch for more papers by this authorD. Larenas, D. Larenas Hospital Médica Sur, Mexico City, MexicoSearch for more papers by this authorJ. Kleine-Tebbe, J. Kleine-Tebbe Allergy & Asthma Center Westend, Berlin, GermanySearch for more papers by this authorL. Jacobsen, L. Jacobsen Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, DenmarkSearch for more papers by this authorG. Passalacqua, G. Passalacqua Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, Genoa, ItalySearch for more papers by this authorP. A. Eng, P. A. Eng Section of Allergy and Pulmonology, Children’s Hospital Aarau and Lucerne, SwitzerlandSearch for more papers by this authorE. M. Varga, E. M. Varga Department of Paediatrics, Respiratory and Allergic Disease Division, Medical University Graz, Graz, AustriaSearch for more papers by this authorE. Valovirta, E. Valovirta Suomen Terveystalo Allergy Clinic, Turku, FinlandSearch for more papers by this authorC. Moreno, C. Moreno Seccion de Alergia, Hospital Reina Sofía, Cordoba, SpainSearch for more papers by this authorH. J. Malling, H. J. Malling Allergy Unit, University Hospital, Copenhagen, DenmarkSearch for more papers by this authorE. Alvarez-Cuesta, E. Alvarez-Cuesta Allergy Division, Ramon & Cajal University Hospital, Alcala de Henares University, Madrid, SpainSearch for more papers by this authorS. Durham, S. Durham National Heart and Lung Institute, Imperial College London, London, UKSearch for more papers by this authorP. Demoly, P. Demoly University Hospital of Montpellier, Montpellier, FranceSearch for more papers by this author First published: 28 June 2011 https://doi.org/10.1111/j.1398-9995.2011.02669.xCitations: 77 Moisés A. Calderón, Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK. Tel.: +44 20 73518024 Fax: +44 20 73497780 E-mail: [email protected] Edited by: Michael Wechsler Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract To cite this article: Calderón MA, Larenas D, Kleine-Tebbe J, Jacobsen L, Passalacqua G, Eng PA, Varga EM, Valovirta E, Moreno C, Malling HJ, Alvarez-Cuesta E, Durham S, Demoly P. European Academy of Allergy and Clinical Immunology task force report on ‘dose–response relationship in allergen-specific immunotherapy’. Allergy 2011; 66: 1345–1359. Abstract Background: For a century, allergen-specific immunotherapy (SIT) has proven to be an effective treatment for allergic rhinitis, asthma, and insect sting allergy. However, as allergen doses are frequently adapted to the individual patient, there are few data on dose-response relationship in SIT. Allergen products for SIT are being increasingly required to conform to regulatory requirements for human medicines, which include the need to demonstrate dose-dependent effects. Methods: This report, produced by a Task Force of the EAACI Immunotherapy Interest Group, evaluates the currently available data on dose-response relationships in SIT and aims to provide recommendations for the design of future studies. Results: Fifteen dose-ranging studies fulfilled the inclusion criteria and twelve reported a dose-response relationship for clinical efficacy. Several studies also reported a dose-response relationship for immunological and safety endpoints. Due to the use of different reference materials and methodologies for the determination of allergen content, variations in study design, and choice of endpoints, no comparisons could be made between studies and, as a consequence, no general dosing recommendations can be made. Conclusion: Despite recently introduced guidelines on the standardization of allergen preparations and study design, the Task Force identified a need for universally accepted standards for the measurement of allergen content in SIT preparations, dosing protocols, and selection of clinical endpoints to enable dose-response effects to be compared across studies. Citing Literature Volume66, Issue10October 2011Pages 1345-1359 RelatedInformation
Publication Year: 2011
Publication Date: 2011-06-28
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 104
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot